Albuminuria
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genetic Association of Albuminuria with Cardiometabolic Disease and Blood Pressure.
|
30220432 |
2018 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension.
|
27618447 |
2016 |
Diastolic blood pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis identifies common and rare variants influencing blood pressure and overlapping with metabolic trait loci.
|
27618448 |
2016 |
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have reported loss-of-function mutations in the chloride channel 7 (CLCN7) gene as a cause of autosomal dominant osteopetrosis type II (ADO-II).
|
19288050 |
2009 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO II) is a rare, heritable bone disorder characterized by a high bone mass and insufficient osteoclast activity.
|
24336069 |
2014 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There are three types of osteopetrosis: autosomal recessive osteopetrosis (ARO), autosomal dominant osteopetrosis type II (ADO II), and intermediate autosomal recessive osteopetrosis (IARO).
|
21962762 |
2012 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the CLCN7 gene result in autosomal dominant osteopetrosis type II (ADO‑II), autosomal recessive osteopetrosis (ARO) and intermediate ARO (IARO).
|
30942407 |
2019 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical Significance of DXA and HR-pQCT in Autosomal Dominant Osteopetrosis (ADO II).
|
29018903 |
2018 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel mutations of CLCN7 cause autosomal dominant osteopetrosis type II (ADO-II) and intermediate autosomal recessive osteopetrosis (IARO) in Chinese patients.
|
26395888 |
2016 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Type II autosomal dominant osteopetrosis (ADO II) is characterized by an increased bone mass that contrasts with the high frequency of fractures.
|
11028441 |
2000 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study we analysed the imaging patterns in two families containing five members with asymptomatic and uncomplicated autosomal dominant osteopetrosis (ADO II), and we report new and uncommon radiological manifestations.
|
19547970 |
2009 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Type II autosomal dominant osteopetrosis (ADO II, Albers-Schonberg disease) is a genetic condition characterized by generalized osteosclerosis predominating in some skeletal sites such as the spine and pelvis.
|
10617161 |
2000 |
Autosomal Dominant Osteopetrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A markedly elevated BB isoenzyme fraction of serum creatine kinase was noted in four male siblings and correlated with typical radiographic findings of autosomal dominant osteopetrosis Type II (ADO Type II).
|
1516225 |
1992 |
Osteopetrosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
There are three types of osteopetrosis: autosomal recessive osteopetrosis (ARO), autosomal dominant osteopetrosis type II (ADO II), and intermediate autosomal recessive osteopetrosis (IARO).
|
21962762 |
2012 |
Osteopetrosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
The G215R mutation in the Cl-/H+-antiporter ClC-7 found in ADO II osteopetrosis does not abolish function but causes a severe trafficking defect.
|
20830208 |
2010 |
Osteopetrosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
They range from a devastating neurometabolic disease, through severe malignant infantile osteopetrosis (OP) to two more benign conditions principally affecting adults [autosomal dominant OP (ADO I and II)].
|
12662317 |
2003 |
Osteopetrosis
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Because some ARO patients have mutations in both copies of the ClCN7 gene, ADO II is allelic with a subset of ARO cases.
|
11741829 |
2001 |
Autosomal Recessive Osteopetrosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the chloride channel 7 gene (CLCN7) lead to chloride channel defect, which results in autosomal dominant osteopetrosis type II (ADO-II), autosomal recessive osteopetrosis (ARO), and intermediate autosomal recessive osteopetrosis (IARO).
|
26395888 |
2016 |
Autosomal Recessive Osteopetrosis
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We present the first Chinese IARO patient with a novel homozygous variant in CLCN7 gene (p. Pro470Leu) and an ADO II patient with a heterozygous variant in CLCN7 gene (p. Arg286Trp).
|
21962762 |
2012 |
Bone Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO-II) is a heritable bone disorder characterized by osteosclerosis, predominantly involving the spine (vertebral end-plate thickening, or rugger-jersey spine), the pelvis ("bone-within-bone" structures) and the skull base.
|
26056022 |
2016 |
Bone Diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Autosomal dominant osteopetrosis type II (ADO II) is a rare, heritable bone disorder characterized by a high bone mass and insufficient osteoclast activity.
|
24336069 |
2014 |
Dyspnea
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
The ability to predict mortality was compared in terms of discrimination by Harrell's C (HC) index and calibration using graphical comparison among the GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2011, GOLD 2017, GOLD grade, BODE (BMI, Airflow Obstruction, Dyspnea, Exercise), updated BODE, BODEx (BMI, Airflow Obstruction, Dyspnea, Exacerbation), e-BODE (Exacerbation and BODE), ADO (Age, Dyspnea, Airflow Obstruction), COPD prognostic index (CPI), and simplified/optimized B-AE-D (BMI, Acute Exacerbation, Dyspnea) indexes.
|
31665736 |
2019 |
Uveomeningoencephalitic Syndrome
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We identified three loci associated with VKH syndrome susceptibility (IL23R-C1orf141, rs117633859, P(combined) = 3.42 × 10(-21), odds ratio (OR) = 1.82; ADO-ZNF365-EGR2, rs442309, P(combined) = 2.97 × 10(-11), OR = 1.37; and HLA-DRB1/DQA1, rs3021304, P(combined) = 1.26 × 10(-118), OR = 2.97).
|
25108386 |
2014 |